Novo Nordisk A/S (NYSE:NVO) secured FDA approval for weight loss pill Wegovy, leading to a 7.30% stock increase. The company cut prices in China and received a Market Perform rating from BMO Capital. Jim Cramer warns of potential resistance from physicians in taking market share from Eli Lilly.

Cramer suggests that physicians may be reluctant to switch patients from Eli Lilly’s weight loss drug to Novo Nordisk’s Wegovy pill due to potential side effects and changes in diet. Physicians prioritize patient toleration of current medications over trying new drugs, which could impact Novo Nordisk’s market share.

Read more at Yahoo Finance: Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill